Research & Development
Formulations containing Hydroxytyrosol from Olive Extract carried in Italian Organic Extra Virgin Olive Oil.
P&P Farma, in collaboration with qualified R&D partners, is constantly evolving the development and control of formulations based on Hydroxytyrosol from Olive Extract carried in Italian Organic Extra Virgin Olive Oil.
Partners for research, development, production, quality control, and clinical evaluation of the FENÒLIA® product range:
Formulation development, production, and final packaging of FENÒLIA® Gastro-resistant Capsules 7.5 carried out at Laboratori Truffini e Reggè , Milan. Gastro-resistant coating process on filled capsules developed and implemented at Laboratori Rofarma Italia, Gaggiano (Milan).
Formulation development, production, and final packaging of the FENÒLIA® Cosmetic Line carried out at Reynaldi Srl, Pianezza (Turin)
Quality control for verifying the Hydroxytyrosol assay in formulation ingredients and finished products, conducted at the Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (ChiBioFarAm) of the University of Messina. An analytical method for determining the Hydroxytyrosol assay in semi-solid formulations (FENÒLIA® Eudermic Cream 15 and FENÒLIA® Eutrophic Oil-Cream 25), unavailable at the time of product development, was specifically developed and validated. Methodology published in the Medicinal Chemistry Journal.
In-vivo Pharmacokinetic study of Hydroxytyrosol released after taking FENÒLIA® Gastro-resistant Capsules 7.5, conducted at the University of Rome “Tor Vergata” and the University of Messina. Results published in Pharmaceutics.
Clinical Nutritional Genomics Study on FENÒLIA® Gastro-resistant Capsules 7.5 conducted at the University of Rome Tor Vergata, Clinical Nutrition and Nutrigenomics Section. Results published in the scientific journals Hindawi Oxidative Medicine and Cellular Longevity and Biomedicine & Preventions
Clinical Study evaluating the combined efficacy and tolerability of Hydroxytyrosol and Vitamin E (via FENÒLIA® Gastro-resistant Capsules) in the treatment of children with Non-Alcoholic Steatohepatitis (NASH), conducted at the Bambino Gesù Children’s Hospital in Rome. Results published in the scientific journals Antioxidants & Redox Signaling, Digestive and Liver Disease and Nutrients.
Clinical Study evaluating the effectiveness of an intervention promoting a healthy lifestyle on the severity of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in children with Down Syndrome (DS), using FENÒLIA® Gastro-resistant Capsules 7.5, conducted at the Bambino Gesù Children’s Hospital in Rome. Results published in the scientific journal Nutrients.
In-vitro Pharmacological Study on a reconstructed human epidermis model to evaluate the efficacy of FENÒLIA® Eudermic Cream 15 in counteracting Atopic Dermatitis, conducted at the University of Messina. Results published in the scientific journal DARU Journal of Pharmaceutical Sciences.
Patch Test on healthy volunteers to verify the tolerability of FENÒLIA® Eudermic Cream 15 and FENÒLIA® Oil Bath 45, conducted by Chelab S.r.l., a Mérieux NutriSciences Company, a spin-off of the University of Padua.
Photopatch Test on healthy volunteers to verify the photosensitivity of FENÒLIA® Eudermic Cream 15, conducted by ISPE S.r.l., Institute for Skin and Product Evaluation, Milan.
Patch Test on healthy volunteers to verify the tolerability of FENÒLIA® Eutrophic Oil-Cream 25, conducted by Bio Basic Europe S.r.l., Milan.
HET-CAM Test on healthy volunteers to verify the ocular irritancy of FENÒLIA® Oil Shampoo 40, conducted by ISPE S.r.l., Institute for Skin and Product Evaluation, Milan.
